Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

• Published in: Haematologica (Roma) Vol. 105; no. 2; pp. 297 - 316
• Main Authors: Yakoub-Agha, Ibrahim, Chabannon, Christian, Bader, Peter, Basak, Grzegorz W., Bonig, Halvard, Ciceri, Fabio, Corbacioglu, Selim, Duarte, Rafael F., Einsele, Hermann, Hudecek, Michael, Kersten, Marie José, Köhl, Ulrike, Kuball, Jürgen, Mielke, Stephan, Mohty, Mohamad, Murray, John, Nagler, Arnon, Robinson, Stephen, Saccardi, Riccardo, Sanchez-Guijo, Fermin, Snowden, John A., Srour, Micha, Styczynski, Jan, Urbano-Ispizua, Alvaro, Hayden, Patrick J., Kröger, Nicolaus
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 2020
• Subjects: Antigens, CD19; Bone Marrow; Cancer; Cell- and Tissue-Based Therapy; Child; Europe; Guideline; Hematology; Human health and pathology; Humans; Immunology; Immunotherapy; Immunotherapy, Adoptive; Life Sciences; Receptors, Antigen, T-Cell - genetics; Receptors, Chimeric Antigen; Young Adult; Europe

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leu...